Trevena Inc (FRA:6T4)
€ 3.825 0 (0%) Market Cap: 1.32 Mil Enterprise Value: 24.14 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100

Trevena Inc to Provide Update Following Recent FDA Approval of OLINVYK Transcript

Aug 10, 2020 / 12:30PM GMT
Release Date Price: €1566.88 (+22.71%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Trevena Conference Call to provide update following recent FDA approval of OLINVYK Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded (Operator Instructions).

I would now like to turn the conference over to your speaker today, Bob Yoder, Chief Business Officer. Thank you. Please go ahead, sir.

Robert T. Yoder
Trevena, Inc. - Senior VP & Chief Business Officer

Thank you. Good morning, and welcome, everyone. Thank you for joining us on this morning's call. With me today are Carrie Bourdow, our President and CEO; Mark Demitrack, our Chief Medical Officer; and Barry Shin, our Chief Financial Officer.

Before we begin, we wish to inform participants that we will be making forward-looking statements on this call. Which are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot